Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
MALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational oral therapy for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and reported financial results for the third quarter ended September 30, 2026.